A Phase 2 interventional study of Interferon Beta-1A and Placebo in Preventive Medicine and Multi Organ Failure, sponsored by Faron Pharmaceuticals Ltd. Terminated at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-14.
Sponsored by Faron Pharmaceuticals Ltd · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm
This trial is multicentre, randomised, double-blinded, Phase II, parallel group comparison study of the efficacy and safety of FP-1201-lyo compared to placebo in patients surviving emergency open surgery for an infra-renal ruptured abdominal aortic aneurysm. Investigational medicinal product will be administered as post-surgical preventive treatment either 10µg FP-1201-lyo or placebo. Treatment will be administered daily every 24 hrs for 6 days. The first dose will be given after successful surgery at the point when the patient arrives to the Intensive Care Unit (ICU).
Both treatment groups will receive standard supportive care.
Aim is randomise and initiate treatment of 152 patients. For the final analysis, a minimum of 129 evaluable patients will be required.
193 studies on the registry are indexed under Multiple Organ Failure; 47 are open to participants now.
This study's enrollment of 40 is below the median of 88 across 90 interventional studies indexed under Multiple Organ Failure.
Browse Multiple Organ Failure studies →Faron Pharmaceuticals Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria during screening and prior to the first dose of study medication being administered on D0 (criteria 1 or 2 and all 3, 4 and 5):
Patients (male or female) presenting with a ruptured abdominal aortic aneurysm (RAAA) diagnosed by ultrasound or CT-scan in the emergency room
Patients (male or female) presenting with symptoms of RAAA known to have an infrarenal AAA and proceeding straight to open repair without radiological assessment and confirmed rupture (=retroperitoneal haematoma) in operation
and
Aneurysma repair must be infra-renal, i.e. the proximal anastomosis must be below the renal arteries and the renal arteries have to stay intact. Temporary above the renal clamping can be used for a maximum of 30 minutes (total clamping time)
and
Patients providing
and
Exclusion Criteria:
To be eligible for inclusion into this study, each patient must not meet any of the following exclusion criteria during screening or prior to the first dose of study medication being administered:
RAAA requiring repair of the renal arteries or the proximal aorta
Note:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days. Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Drug: Interferon Beta-1A
FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days. Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection
Drug: Placebo
Lyophilisate for solution for injection.
Also known as: FP-1201-lyo, ATC code L03AB07
Lyophilisate for solution for injection as placebo.
Also known as: Placebo for investigational drug
The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality
Number of fatalities
Time frame: Day 30
The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality
Number of fatalities
Time frame: Day 90
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Ventilator Free Days (VFDs)
Number of ventilator free days. VFDs to Day 30 were defined as the number of calendar days after initiating unassisted breathing (UAB) to Day 30 from first treatment, assuming that a patient survives at least 48 consecutive hours after initiating UAB. Patients who die without initiating UAB were assigned a VFD value of zero.
Time frame: Day 30
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Days Receiving Hemodialysis
Number of days receiving hemodialysis. There were only few reported values other than zero.
Time frame: Day 30 and Day 90
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Organ Failure Free Days by Means of the Sequential Organ Failure Assessment (SOFA) Score
Organ failure free days were defined as the number of days in the first 30 days after the first dose of study medication that the patient was alive and free of organ failure with a SOFA score of zero for the following six organ parameters: respiration, coagulation, liver, cardiovascular, central nervous system and renal function. It is graded from 0 to 4 according to the degree of dysfunction/ failure (higher scores indicate more severe organ failure). Patients who died without achieving a SOFA score of zero was assigned an organ failure free days value of zero. Note: the information for organ failure free days has been only collected when the patients have been in the Intensive Care Unit (ICU). As ICU free days have been reported in a separate variable, it was decided that presented information will be kept, without trying to conduct imputation.
Time frame: Day 30
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Prevalence of Abdominal Compartment Syndrome by Intra-abdominal Pressure (IAP)
Intra-abdominal pressure values, which were routinely measured during ICU stay via urine bladder catheter.
Time frame: Days 1 - 6, D9 and D13 during Intensive Care Unit (ICU) stay
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Neutralizing Antibodies Against IFN Beta-1a (NAbs) in Whole Blood Samples
IFN beta-1a neutralizing antibodies immune response. Blood samples for the NAbs assessments were collected at Day 0 pre-dose (baseline) and at Day 30.
Time frame: Day 30
The Efficacy of FP-1201-lyo Compared to Placebo Concerning Disability by Modified Ranking Scale (mRS).
Scale gives the degree of disability or dependence in the daily activities. Single mRS value is applied for every patient based on patient or caregiver interview. The scale runs from 0-6, from perfect health without symptoms to death. Pre-operation Baseline Visit mRS value is collected for reference.
Time frame: Day 90
Safety Parameters of Clinically Significant Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events, Vital Signs and Clinical Laboratory Parameters
Number of TEAEs from vital signs data, laboratory data, physical examinations and spontaneous reporting when conscious.
Time frame: Day 0 to Day 30
Pharmacoeconomic Information of Length of ICU Stay, Length of Hospital Stay, Length of Stay at Another Health Care Facility, Length of Hemodialysis Needed, Ventilation Free Days
Economic measurement: * Length of ICU stay, in terms of ICU free days at D30 * Length of hospital stay, in terms of hospital free days at D90 * Length of stay at another health care facility at D90 * The number of days on hemodialysis at D30 and at D90 * The number of organ failure free days at D30 * The number of ventilation free days at D30
Time frame: Day 30 or Day 90
Myxovirus Resistant Protein A (MxA) Concentration in Whole Blood Samples as Pharmacodynamic Marker
Concentration of Myxovirus Resistant Protein A (MxA)
Time frame: Day 0 up to Day 13
Tentative Disease Specific Marker Cluster of Differentiation 73 (CD73, Ecto-5'-Nucleotidase Enzyme) Concentration in Serum Samples
CD73 (ecto-5'-nucleotidase enzyme) concentration
Time frame: Day 0 up to Day 13
Tentative Disease Specific, Potential Inflammatory Marker - Interleukin 6 (IL-6) in Serum Samples
IL-6 concentration.
Time frame: Day 0 up to Day 13
Tentative Disease Specific, Potential Inflammatory Marker - Hepatocyte Growth Factor [HGF]) in Serum Samples
HGF concentration.
Time frame: Day 0 up to Day 13
| Milestone | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Started | 29 | 11 |
| Completed | 22 | 8 |
| Not completed | 7 | 3 |
| Withdrew: Death | 4 | 1 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Started | 25 | 10 |
| Completed | 22 | 9 |
| Not completed | 3 | 1 |
| Withdrew: Death | 3 | 1 |
Number of fatalities
| Participants | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality | 6 | 2 |
Number of fatalities
| Participants | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| The Efficacy of FP-1201-lyo Compared to Placebo Concerning All Cause Mortality | 7 | 2 |
Number of ventilator free days. VFDs to Day 30 were defined as the number of calendar days after initiating unassisted breathing (UAB) to Day 30 from first treatment, assuming that a patient survives at least 48 consecutive hours after initiating UAB. Patients who die without initiating UAB were assigned a VFD value of zero.
| days | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Ventilator Free Days (VFDs) | 25.0 (0.0 to 30.0) | 29.0 (0.0 to 29.0) |
Number of days receiving hemodialysis. There were only few reported values other than zero.
| days | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Day 30 | 0.9 ± 4.15 | 0.0 ± 0.00 |
| Day 90 | 0.6 ± 2.68 | 0.0 ± 0.00 |
Organ failure free days were defined as the number of days in the first 30 days after the first dose of study medication that the patient was alive and free of organ failure with a SOFA score of zero for the following six organ parameters: respiration, coagulation, liver, cardiovascular, central nervous system and renal function. It is graded from 0 to 4 according to the degree of dysfunction/ failure (higher scores indicate more severe organ failure). Patients who died without achieving a SOFA score of zero was assigned an organ failure free days value of zero. Note: the information for organ failure free days has been only collected when the patients have been in the Intensive Care Unit (ICU). As ICU free days have been reported in a separate variable, it was decided that presented information will be kept, without trying to conduct imputation.
| days | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| The Efficacy of FP-1201-lyo Compared to Placebo Concerning Number of Organ Failure Free Days by Means of the Sequential Organ Failure Assessment (SOFA) Score | 0.0 ± 0.00 | 0.0 ± 0.00 |
Intra-abdominal pressure values, which were routinely measured during ICU stay via urine bladder catheter.
| mmHg | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Day 1 | 15.4 ± 12.37 | 10.3 ± 4.80 |
| Day 2 | 12.2 ± 3.58 | 12.1 ± 6.01 |
| Day 3 | 13.1 ± 4.62 | 10.3 ± 5.35 |
| Day 4 | 11.4 ± 6.60 | 8.6 ± 5.32 |
| Day 5 | 10.5 ± 3.14 | 12.5 ± 5.45 |
| Day 6 | 11.4 ± 5.29 | 15.0 ± 0 |
| Day 9 | 11.0 ± 5.48 | — |
| Day 13 | 10.8 ± 4.49 | — |
IFN beta-1a neutralizing antibodies immune response. Blood samples for the NAbs assessments were collected at Day 0 pre-dose (baseline) and at Day 30.
| Participants | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Baseline | 0 | 0 |
| Day 30 | 0 | 0 |
Scale gives the degree of disability or dependence in the daily activities. Single mRS value is applied for every patient based on patient or caregiver interview. The scale runs from 0-6, from perfect health without symptoms to death. Pre-operation Baseline Visit mRS value is collected for reference.
| Participants | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| No symptoms - 0 | 5 | 2 |
| No significant disability - 1 | 5 | 5 |
| Slight disability - 2 | 3 | 1 |
| Moderate disability - 3 | 2 | 0 |
| Moderately severe disability - 4 | 3 | 0 |
| Severe disability - 5 | 2 | 1 |
| Death - 6 | 7 | 2 |
Number of TEAEs from vital signs data, laboratory data, physical examinations and spontaneous reporting when conscious.
| Events | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Product-related TEAEs | 17 | 1 |
| Severe TEAEs | 28 | 2 |
| Serious TEAEs | 26 | 5 |
| TEAEs Leading to Study Product Discontinuation | 7 | 1 |
| TEAEs Leading to Death | 7 | 1 |
Economic measurement: * Length of ICU stay, in terms of ICU free days at D30 * Length of hospital stay, in terms of hospital free days at D90 * Length of stay at another health care facility at D90 * The number of days on hemodialysis at D30 and at D90 * The number of organ failure free days at D30 * The number of ventilation free days at D30
| days | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| ICU free days at Day 30 | 16.8 ± 12.39 | 21.9 ± 11.06 |
| Days in hospital at Day 90 | 18.1 ± 9.84 | 13.8 ± 9.97 |
| Days in another facility at Day 90 | 11.8 ± 23.79 | 7.0 ± 19.80 |
| Days on hemodialysis at Day 30 | 0.9 ± 4.15 | 0.0 ± 0.00 |
| Days on hemodialysis at Day 90 | 0.6 ± 2.68 | 0.0 ± 0.00 |
| Organ failure free days at Day 30 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Ventilation free days at Day 30 | 20.6 ± 10.62 | 25.1 ± 8.85 |
Concentration of Myxovirus Resistant Protein A (MxA)
| ng/mL | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Baseline | 3.5 (2.4 to 5.1) | 6.0 (3.3 to 11.0) |
| Day 1 | 15.0 (10.2 to 22.1) | 5.1 (2.8 to 9.3) |
| Day 2 | 19.8 (13.5 to 29.1) | 3.8 (2.1 to 7.0) |
| Day 3 | 21.2 (14.3 to 31.4) | 3.3 (1.8 to 6.2) |
| Day 4 | 36.4 (24.4 to 54.2) | 4.1 (2.2 to 7.7) |
| Day 5 | 48.3 (32.3 to 72.3) | 3.1 (1.6 to 5.8) |
| Day 6 | 50.4 (33.9 to 75.1) | 3.6 (1.9 to 6.8) |
| Day 9 | 14.3 (9.5 to 21.5) | 4.8 (2.4 to 9.7) |
| Day 13 | 3.9 (2.5 to 5.9) | 8.7 (3.7 to 20.7) |
CD73 (ecto-5'-nucleotidase enzyme) concentration
| ng/mL | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Baseline | 2.1 (1.8 to 2.5) | 2.2 (1.7 to 2.9) |
| Day 1 | 2.0 (1.7 to 2.4) | 2.2 (1.6 to 2.8) |
| Day 2 | 2.2 (1.8 to 2.6) | 2.2 (1.7 to 3.0) |
| Day 3 | 2.0 (1.7 to 2.4) | 2.3 (1.7 to 3.1) |
| Day 4 | 2.3 (1.9 to 2.8) | 2.6 (1.9 to 3.5) |
| Day 5 | 3.0 (2.4 to 3.6) | 3.5 (2.6 to 4.8) |
| Day 6 | 3.8 (3.2 to 4.6) | 3.8 (2.7 to 5.2) |
| Day 9 | 3.9 (3.2 to 4.8) | 3.8 (2.6 to 5.4) |
| Day 13 | 2.9 (2.3 to 3.6) | 2.7 (1.7 to 4.3) |
IL-6 concentration.
| pg/mL | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Baseline | 328.9 (223.8 to 483.3) | 378.9 (207.3 to 692.6) |
| Day 1 | 493.1 (335.5 to 724.5) | 460.2 (251.8 to 841.0) |
| Day 3 | 181.4 (122.0 to 270.0) | 130.7 (69.8 to 244.8) |
| Day 6 | 164.1 (108.1 to 249.2) | 79.1 (39.8 to 157.1) |
| Day 9 | 107.9 (69.9 to 166.5) | 74.5 (34.4 to 161.5) |
HGF concentration.
No measurements were reported for this outcome.
Collected over The Adverse Event (AE) reporting period was up to study D30. In accordance with the protocol, the investigators reported AEs occurring after D30 only if the investigator considered a causal relationship with the study drug. All deaths were reported as SAEs throughout the study, up until D90.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FP-1201-lyo 10 µg | 7/29 (24.1%) | 13/29 (44.8%) | 27/29 (93.1%) |
| FP-1201-lyo Placebo | 2/11 (18.2%) | 3/11 (27.3%) | 9/11 (81.8%) |
| Event | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Multiple organ dysfunction syndromeGeneral disorders | 4/29 | 0/11 |
| Intestinal ischaemiaGastrointestinal disorders | 3/29 | 1/11 |
| Large intestine perforationGastrointestinal disorders | 3/29 | 0/11 |
| PneumoniaInfections and infestations | 0/29 | 1/11 |
| Pulmonary contusionInjury, poisoning and procedural complications | 0/29 | 1/11 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/29 | 1/11 |
| Sternal fractureInjury, poisoning and procedural complications | 0/29 | 1/11 |
| Gastrointestinal necrosisGastrointestinal disorders | 2/29 | 0/11 |
| Myocardial ischaemiaCardiac disorders | 1/29 | 0/11 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/29 | 0/11 |
| Event | FP-1201-lyo 10 µg | FP-1201-lyo Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 5/29 | 3/11 |
| PyrexiaGeneral disorders | 6/29 | 1/11 |
| Confusional statePsychiatric disorders | 4/29 | 2/11 |
| HypertensionVascular disorders | 4/29 | 2/11 |
| Haemoglobin decreasedInvestigations | 4/29 | 1/11 |
| ConstipationGastrointestinal disorders | 3/29 | 0/11 |
| C-reactive protein increasedInvestigations | 3/29 | 1/11 |
| Hepatic enzyme increasedInvestigations | 3/29 | 0/11 |
| HypokalaemiaMetabolism and nutrition disorders | 3/29 | 1/11 |
| Haemorrhagic anaemiaBlood and lymphatic system disorders | 0/29 | 1/11 |
A total of 40 subjects received at least 1 dose of study drug. 2 patients were excluded from Full Analysis Set for Efficacy (FAS-E) and Per Protocol Set (PPS) populations due to early deaths (within 36 hours from first dose of the study treatment). Therefore, FAS-E and PPS populations consisted of 38 patients.
| Age, Customized(Participants) | FP-1201-lyo 10 µg | FP-1201-lyo Placebo | Total |
|---|---|---|---|
| < 70 years | 7 | 3 | 10 |
| 70-80 years | 14 | 6 | 20 |
| > 80 years | 6 | 2 | 8 |
| Sex: Female, Male(Participants) | FP-1201-lyo 10 µg | FP-1201-lyo Placebo | Total |
|---|---|---|---|
| Female | 4 | 0 | 4 |
| Male | 23 | 11 | 34 |
| Race (NIH/OMB)(Participants) | FP-1201-lyo 10 µg | FP-1201-lyo Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 27 | 11 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | FP-1201-lyo 10 µg | FP-1201-lyo Placebo | Total |
|---|---|---|---|
| Finland | 23 | 8 | 31 |
| Lithuania | 3 | 1 | 4 |
| Estonia | 1 | 2 | 3 |
| Baseline Height(centimetres) | FP-1201-lyo 10 µg | FP-1201-lyo Placebo | Total |
|---|---|---|---|
| Mean | 172.3 ± 6.34 | 177.5 ± 7.59 | 173.8 ± 7.05 |
| Baseline Weight(kilograms) | FP-1201-lyo 10 µg | FP-1201-lyo Placebo | Total |
|---|---|---|---|
| Mean | 82.0 ± 16.14 | 95.9 ± 21.21 | 86.0 ± 18.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Sep 2019, 31 months.
Results were first posted in Jan 2021, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Faron Pharmaceuticals Ltd